|Mr. Gregory J. Divis Jr.||CEO & Director||897k||N/A||1967|
|Mr. Thomas S. McHugh||Sr. VP & CFO||581.2k||N/A||1965|
|Dr. Jordan S. Dubow M.D.||Consultant||727.93k||395.25k||1978|
|Mr. Gregory J. Davis||VP of Corp. and Bus. Devel.||N/A||N/A||1965|
|Mr. Mark W. Elrod||VP of Sales||N/A||N/A||N/A|
|Ms. Angie Woods||VP of People & Culture||N/A||N/A||N/A|
|Mr. Christian Kalita Pharm.D||Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs||N/A||N/A||N/A|
|Mr. Steven G. Sullivan||VP of Sales & Marketing and Head of Commercial Operations||N/A||N/A||1965|
|Dr. Jason M. Vaughn||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Mr. Richard Kim||Chief Commercial Officer||N/A||N/A||1969|
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.